CHA Vaccine Research Institute Balance Sheet Health
Financial Health criteria checks 6/6
CHA Vaccine Research Institute has a total shareholder equity of ₩31.5B and total debt of ₩4.4B, which brings its debt-to-equity ratio to 14.1%. Its total assets and total liabilities are ₩41.8B and ₩10.3B respectively.
Key information
14.1%
Debt to equity ratio
₩4.44b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩35.15b |
| Equity | ₩31.51b |
| Total liabilities | ₩10.27b |
| Total assets | ₩41.78b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A261780's short term assets (₩39.2B) exceed its short term liabilities (₩683.5M).
Long Term Liabilities: A261780's short term assets (₩39.2B) exceed its long term liabilities (₩9.6B).
Debt to Equity History and Analysis
Debt Level: A261780 has more cash than its total debt.
Reducing Debt: A261780 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A261780 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A261780 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.1% each year